-
Mashup Score: 154
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 150
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 149
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 149
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 146
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 146
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Regeneron Provides Update on Biologics License Application for Odronextamab | Regeneron Pharmaceuticals Inc. - 2 month(s) ago
TARRYTOWN, N.Y. , March 25, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)
Source: investor.regeneron.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Regeneron Provides Update on Biologics License Application for Odronextamab | Regeneron Pharmaceuticals Inc. - 2 month(s) ago
TARRYTOWN, N.Y. , March 25, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)
Source: investor.regeneron.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
npj Digital Medicine – The lucent yet opaque challenge of regulating artificial intelligence in radiology
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 39Thrombotic complications of immune thrombocytopenic purpura - 2 month(s) ago
A 74-year-old woman with longstanding, refractory immune thrombocytopenic purpura presented to the Austin Hospital (Melbourne, Australia) in March, 2021, with severe unilateral right leg swelling. Ultrasound confirmed occlusive right common femoral and external iliac vein thromboses. In the context of persistent severe thrombocytopenia (platelet count 31 × 109 platelets per L), she commenced intravenous therapeutic unfractionated heparin. However, her platelet count dropped to 21 × 109 platelets per L.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet
RT @DavidJuurlink: It’s finally out. Please stop giving Paxlovid to vaccinated people. https://t.co/5ZdNA1OJdY